Byrne Asset Management LLC Sells 185 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Byrne Asset Management LLC decreased its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 21.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 667 shares of the financial services provider’s stock after selling 185 shares during the period. Byrne Asset Management LLC’s holdings in iShares Biotechnology ETF were worth $88,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Darwin Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $29,000. Highline Wealth Partners LLC purchased a new stake in iShares Biotechnology ETF in the 3rd quarter worth $30,000. HHM Wealth Advisors LLC boosted its position in shares of iShares Biotechnology ETF by 200.0% during the fourth quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock worth $30,000 after acquiring an additional 150 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in shares of iShares Biotechnology ETF during the 3rd quarter valued at about $36,000. Finally, Hager Investment Management Services LLC bought a new stake in iShares Biotechnology ETF in the 4th quarter worth approximately $34,000. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Trading Down 2.1 %

IBB stock opened at $137.67 on Friday. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57. The company has a fifty day simple moving average of $136.22 and a two-hundred day simple moving average of $141.41.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.